Plain-English translation of NCT06354530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing two different ways to treat locally advanced esophageal squamous cell carcinoma before surgery. One approach combines immunotherapy, chemotherapy, and a medication called . The other combines immunotherapy with chemotherapy and radiation therapy given at the same time. The trial will compare how safe and effective each approach is.
Esophageal cancer is serious, and doctors want to find the best way to treat it before surgery to give patients the best chance of recovery. This trial will help determine which treatment combination works better and is safer for patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive one of two treatment plans. One group will take the medication along with immunotherapy and chemotherapy before surgery; the other group will receive immunotherapy combined with chemotherapy and radiation therapy before surgery. You will have regular clinic visits for treatment, blood tests, and imaging scans to monitor your progress. After the treatment phase, you will have surgery to remove the cancer, followed by ongoing follow-up care to track your recovery and long-term outcomes.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China